hnRNP A2/B1 Antibody #25734
- WB
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 34-36 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
hnRNP A2/B1 Antibody detects endogenous levels of total hnRNP A2/B1 protein. This antibody does not cross-react with other hnRNP proteins.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr41 of human hnRNP A2/B1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) is a member of the hnRNP A/B family of related RNA-binding proteins that bind pre-mRNA and are involved in the processing, metabolism, and transport of nuclear pre-mRNA transcripts (1). Alternative splicing produces transcripts that encode two homologous hnRNP proteins, hnRNPA2 and hnRNPB1, from a single gene sequence (2). Studies demonstrate hnRNP A2/B1 splicing repression across multiple targets (3,4) and that both proteins can bind and protect telomere repeat sequences from DNase digestion (5,6). Altered expression of hnRNP B1 is seen in several forms of cancer, including squamous cell carcinoma, adenocarcinoma, and various forms of lung cancer (7). Overexpression of hnRNP B1 may be associated with inhibition of DNA-PK activity and impaired DNA repair during early stages of cancer development (8). Autoantigens to hnRNP A2/B1 (termed RA33) are associated with rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease (9-11).
- Myer, V.E. and Steitz, J.A. (1995) RNA 1, 171-82.
- Kozu, T. et al. (1995) Genomics 25, 365-71.
- Clower, C.V. et al. (2010) Proc Natl Acad Sci USA 107, 1894-9.
- Moran-Jones, K. et al. (2009) Cancer Res 69, 9219-27.
- Moran-Jones, K. et al. (2005) Nucleic Acids Res 33, 486-96.
- Kamma, H. et al. (2001) Biochem Biophys Res Commun 280, 625-30.
- Hamasaki, M. et al. (2001) Anticancer Res 21, 979-84.
- Iwanaga, K. et al. (2005) Biochem Biophys Res Commun 333, 888-95.
- Fritsch, R. et al. (2002) J Immunol 169, 1068-76.
- Fritsch-Stork, R. et al. (2006) Arthritis Res Ther 8, R118.
- Skriner, K. et al. (1997) J Clin Invest 100, 127-35.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.